Goldshield Grp PLC - Acquisition

RNS Number:6522L
Goldshield Group PLC
5 June 2000

    Acquisition of Nitrofurantoin Range for Portugal

The  Directors  of Goldshield Group PLC  are  pleased  to
announce the acquisition of licenses, trademarks and know-
how  for  Portugal for Furadantin from Procter  &  Gamble
Pharmaceuticals,  Inc. ("Procter & Gamble")  for  a  cash
consideration  of  US $3.29 million payable  in  full  on
completion.  Sales of this product in Portugal for the 12
months to 30 April 2000 were US $1.19 million.

Furadantin  is  part of the Nitrofurantoin product  range
and is used for the treatment of urinary infections.

On   20   September  1999  the  Company   announced   the
acquisition  of  the  Nitrofurantoin  range  of  products
relating  to  several  other  European  territories  from
Procter  &  Gamble.  Procter and Gamble will continue  to
market the Nitrofurantoin products in the United States.

Ajit  Patel,  Chairman and Chief Executive of  Goldshield
Group PLC, said:

     "The Nitrofurantoin rights for Portugal complete our
     European range for these products."


For Further Information Please Contact:

Goldshield Group plc
Ajit Patel, Chairman and Chief Executive
Tel: [phone]

Buchanan  Communications           Tel:  + 44 (0) 20466 5000
Nicola How/Nicola Cronk


Notes to editors:

Goldshield  Group plc: a profitable, British,  marketing-
led,  emerging pharmaceutical company based  in  Croydon,
Surrey,  was  founded  in 1990, to  sell  healthcare  and
pharmaceutical products internationally.   In  June  1998
Goldshield  floated  on  the London  Stock  Exchange  and
currently  has  a market capitalisation  of  around  #250
million.


END
ACQEAPKAELKEEFE